These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 38199897)

  • 21. Novel treatment strategies for hematological malignancies in the immunotherapy era.
    Imai Y
    Int J Hematol; 2024 Jul; 120(1):3-5. PubMed ID: 38861242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in multiple myeloma.
    Asensi Cantó P; Arnao Herraiz M; de la Rubia Comos J
    Med Clin (Barc); 2024 May; 162(10):485-493. PubMed ID: 38218655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
    Parikh RH; Lonial S
    CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
    Nath K; Shekarkhand T; Nemirovsky D; Derkach A; Costa BA; Nishimura N; Farzana T; Rueda C; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Korde N; Shah UA; Tan CR; Hultcrantz M; Giralt SA; Usmani SZ; Shahid Z; Mailankody S; Lesokhin AM
    Blood Cancer J; 2024 May; 14(1):88. PubMed ID: 38821925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bispecific antibodies for multiple myeloma: past, present and future.
    Ochi T; Konishi T; Takenaka K
    Int J Hematol; 2024 Jul; 120(1):23-33. PubMed ID: 38613724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.
    Howard AJ; Concepcion I; Wang AX; Hamadeh IS; Hultcrantz M; Mailankody S; Tan C; Korde N; Lesokhin AM; Hassoun H; Shah UA; Maclachlan KH; Rajeeve S; Landau HJ; Scordo M; Shah GL; Lahoud OB; Chung DJ; Giralt S; Usmani SZ; Firestone RS
    Blood Adv; 2024 Jun; 8(12):3246-3253. PubMed ID: 38621239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic progress in relapsed/refractory multiple myeloma.
    Chen Q; Zhang M; Zheng S; Tong Y; Tan Y
    Ann Hematol; 2024 Jun; 103(6):1833-1841. PubMed ID: 38609727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting GPRC5D in multiple myeloma.
    Elemian S; Al Hadidi S
    Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies.
    Nath K; Mailankody S; Usmani SZ
    Hematol Oncol Clin North Am; 2023 Dec; 37(6):1201-1214. PubMed ID: 37330347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
    Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
    Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
    Martino M; Paviglianiti A
    Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting BCMA in Multiple Myeloma.
    Tan CR; Shah UA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy.
    Wang M; Wang C; Deng J; Wang H; Sun C; Luo S; Hu Y
    Front Biosci (Landmark Ed); 2024 Jun; 29(6):216. PubMed ID: 38940040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.